Cigna ends GLP-1 obesity drug coverage for its own employee health plan

Cigna has dropped coverage for GLP-1 obesity drugs, including Wegovy and Zepbound, from its own employee health plan, citing cost. This follows Cigna's earlier move to exclude the drugs for its PBM employer clients. The decision reflects the intense cost pressure these drugs place on commercial plans. For practices with Cigna commercial patients, expect increased prior authorization scrutiny and potential denials for GLP-1 prescriptions for obesity. Verify patient-specific pharmacy benefits before prescribing and prepare robust documentation of medical necessity, including comorbid conditions.